Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

2017-08-01
Price :
Published : Aug-2017
No. of Pages : 136
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Liver Cancer Diagnostic Tests Overview 8
3 Products under Development 9
3.1 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
3.2 Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
3.3 Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
3.4 Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
4 Liver Cancer Diagnostic Tests - Pipeline Products under Development by Companies 13
4.1 Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 13
4.2 Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 15
5 Liver Cancer Diagnostic Tests Companies and Product Overview 17
5.1 Abbott Diagnostics Company Overview 17
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
5.2 Abcodia Ltd Company Overview 22
5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
5.3 AXO Science SAS Company Overview 23
5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 23
5.4 BioMark Technologies Inc Company Overview 26
5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.5 Bioprognos SL Company Overview 27
5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 27
5.6 China Sky One Medical Inc Company Overview 28
5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.7 Digna Biotech SL Company Overview 29
5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 29
5.8 Drexel University Company Overview 31
5.8.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
5.9 Exact Sciences Corp Company Overview 33
5.9.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
5.10 German Cancer Research Center Company Overview 34
5.10.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34
5.11 Glycotest Inc Company Overview 35
5.11.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.12 ImCare Biotech LLC Company Overview 36
5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 36
5.13 Imperial College London Company Overview 37
5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 37
5.14 IntegraGen SA Company Overview 38
5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 38
5.15 Matrix-Bio, Inc. Company Overview 39
5.15.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
5.16 NanoString Technologies Inc Company Overview 41
5.16.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.17 National Cancer Institute US Company Overview 42
5.17.1 National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview 42
5.18 Oncimmune (USA) LLC Company Overview 44
5.18.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
5.19 Orion Genomics LLC Company Overview 45
5.19.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
5.20 PleX Diagnostics Inc (Inactive) Company Overview 46
5.20.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46
5.21 ProMIS Neurosciences Inc Company Overview 47
5.21.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 47
5.22 Proplex Technologies Llc Company Overview 48
5.22.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 48
5.23 Proteome Sciences Plc Company Overview 49
5.23.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 49
5.24 Roche Diagnostics International Ltd Company Overview 50
5.24.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
5.25 University of Rochester Company Overview 52
5.25.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 52
5.26 Ventana Medical Systems Inc Company Overview 53
5.26.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 53
5.27 Viomics Inc. Company Overview 54
5.27.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
5.28 XEPTAGEN SpA Company Overview 55
5.28.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 55
5.29 Xiamen Zeesan Biotech Co.,Ltd Company Overview 60
5.29.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
6 Liver Cancer Diagnostic Tests - Recent Developments 61
6.1 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 61
6.2 Jul 11, 2017: Integragen Reports Continued Growth During 1st Half Of 2017 61
6.3 Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 62
6.4 Jul 10, 2017: ProMIS Neurosciences Provides Second Quarter Update for 2017 62
6.5 Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 63
6.6 Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 64
6.7 Jun 12, 2017: Proteome Sciences: New Registered Address 65
6.8 Jun 06, 2017: ProMIS Neurosciences Appoints William C. Mobley to Scientific Advisory Board 65
6.9 May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 66
6.10 May 10, 2017: NanoString Appoints Elisha W. Finney to Board of Directors 67
6.11 May 09, 2017: ProMIS Neurosciences Announces Q1 2017 Quarterly Results 68
6.12 May 04, 2017: PerkinElmer Announces Financial Results for the First Quarter of 2017 69
6.13 May 04, 2017: NanoString Technologies Releases Operating Results for First Quarter of 2017 70
6.14 May 03, 2017: Blueprint Medicines Reports First Quarter 2017 Financial Results 71
6.15 May 02, 2017: Pfizer Reports First-Quarter 2017 Results 72
6.16 Apr 21, 2017: IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%) 77
6.17 Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 80
6.18 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer 81
6.19 Mar 30, 2017: ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near term value creation 82
6.20 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM 82
6.21 Mar 23, 2017: PerkinElmer to Display Portfolio of Cancer Research Technologies and Workflow Solutions at 2017 AACR Annual Meeting 91
6.22 Mar 22, 2017: ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer 93
6.23 Mar 15, 2017: Trovagene Reports Fourth Quarter and Year End 2016 Financial Results 93
6.24 Mar 15, 2017: ProMIS Neurosciences Announces Fiscal 2016 Annual Results 94
6.25 Mar 09, 2017: Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results 96
6.26 Mar 02, 2017: ProMIS Neurosciences announces appointment of Anthony Giovinazzo to its Board of Directors 98
6.27 Mar 01, 2017: NanoString Technologies Releases Fourth Quarter and Full Year 2016 Operating Results and Provides 2017 Outlook 99
6.28 Feb 27, 2017: The Novartis Institutes for BioMedical Research and NanoString Technologies Demonstrates at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 100
6.29 Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer's Board of Directors 101
6.30 Feb 02, 2017: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016 101
6.31 Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 103
6.32 Jan 10, 2017: NanoString Technologies Provides Preliminary Operational and Financial Results for 2016 109
6.33 Jan 09, 2017: IntegraGen Reports Sharp Increase in Sales During 2016 110
6.34 Nov 21, 2016: Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire 110
6.35 Nov 14, 2016: Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role 111
6.36 Nov 10, 2016: Blueprint Medicines Reports Third Quarter 2016 Financial Results 112
6.37 Nov 09, 2016: Trovagene Reports Third Quarter 2016 Financial Results and Accomplishments 113
6.38 Nov 07, 2016: PerkinElmer Announces Financial Results for the Third Quarter of 2016 115
6.39 Nov 02, 2016: ProMIS Neurosciences Announces Third Quarter 2016 Results 116
6.40 Nov 02, 2016: NanoString Technologies Releases Operating Results for Third Quarter of 2016 117
6.41 Nov 01, 2016: Pfizer Reports Third-Quarter 2016 Results 118
6.42 Oct 18, 2016: ProMIS Neurosciences announces appointment of Dr. Richard Gregory to its Board of Directors 124
6.43 Oct 17, 2016: PerkinElmer Elects Samuel Chapin to Board of Directors 124
6.44 Oct 14, 2016: IntegraGen Reports Revenues for First Half of 2016 125
6.45 Sep 26, 2016: Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation 126
6.46 Sep 26, 2016: PerkinElmer Announces New Organizational Structure 127
6.47 Sep 15, 2016: Proteome Sciences: Interim Results 128
6.48 Sep 07, 2016: Pfizer Appoints Chief Scientific Officer for Neuroscience Research 128
6.49 Sep 06, 2016: Blueprint Medicines Announces Appointment of Tracey McCain as Chief Legal Officer and Executive Vice President 129
6.50 Aug 12, 2016: ProMIS Neurosciences Announces Second Quarter 2016 Results 129
6.51 Aug 09, 2016: Blueprint Medicines Reports Second Quarter 2016 Financial Results 131
7 Appendix 133
7.1 Methodology 133
7.2 About GlobalData 136
7.3 Contact Us 136
7.4 Disclaimer 136

1.1 List of Tables
Table 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
Table 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
Table 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
Table 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
Table 5: Liver Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 13
Table 6: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 15
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 17
Table 8: ARCHITECT c16000 System - PIVKA Assay - Product Status 17
Table 9: ARCHITECT c16000 System - PIVKA Assay - Product Description 18
Table 10: ARCHITECT c4000 System - PIVKA Assay - Product Status 18
Table 11: ARCHITECT c4000 System - PIVKA Assay - Product Description 18
Table 12: ARCHITECT c8000 System - PIVKA Assay - Product Status 19
Table 13: ARCHITECT c8000 System - PIVKA Assay - Product Description 19
Table 14: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Status 19
Table 15: ARCHITECT ci16200 Integrated System - PIVKA Assay - Product Description 20
Table 16: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Status 20
Table 17: ARCHITECT ci4100 Integrated System - PIVKA Assay - Product Description 20
Table 18: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Status 21
Table 19: ARCHITECT ci8200 Integrated System - PIVKA Assay - Product Description 21
Table 20: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 22
Table 21: Biomarker Test - Liver Cancer - Product Status 22
Table 22: Biomarker Test - Liver Cancer - Product Description 22
Table 23: AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 23
Table 24: Multiplexed Detection - Des-Carboxy Prothrombin - Product Status 23
Table 25: Multiplexed Detection - Des-Carboxy Prothrombin - Product Description 23
Table 26: Multiplexed Detection - Matrix metalloproteinase 1 - Product Status 24
Table 27: Multiplexed Detection - Matrix metalloproteinase 1 - Product Description 24
Table 28: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Status 24
Table 29: Multiplexed Detection - Procollagen type III N-terminal peptide - Product Description 25
Table 30: BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 26
Table 31: Biomarker Assay - Hepatocellular Cancer - Product Status 26
Table 32: Biomarker Assay - Hepatocellular Cancer - Product Description 26
Table 33: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 27
Table 34: MBDAA Liver Cancer Test - Product Status 27
Table 35: MBDAA Liver Cancer Test - Product Description 27
Table 36: China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 37: Diagnostic Kit - Liver Cancer - Product Status 28
Table 38: Diagnostic Kit - Liver Cancer - Product Description 28
Table 39: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 29
Table 40: HCC Molecular Marker Assay - Product Status 29
Table 41: HCC Molecular Marker Assay - Product Description 29
Table 42: Oxidated APO-A1 Assay - Product Status 30
Table 43: Oxidated APO-A1 Assay - Product Description 30
Table 44: Drexel University Pipeline Products & Ongoing Clinical Trials Overview 31
Table 45: Diagnostic Test - Liver Cancer - Product Status 31
Table 46: Diagnostic Test - Liver Cancer - Product Description 31
Table 47: Glycan-Based Biomarker Assay - Liver Cancer - Product Status 32
Table 48: Glycan-Based Biomarker Assay - Liver Cancer - Product Description 32
Table 49: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 33
Table 50: Blood-based Liver Cancer Test - Product Status 33
Table 51: Blood-based Liver Cancer Test - Product Description 33
Table 52: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34
Table 53: RAGE Based Diagnostic Assay - Liver Cancer - Product Status 34
Table 54: RAGE Based Diagnostic Assay - Liver Cancer - Product Description 34
Table 55: Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35
Table 56: HCC Panel - Product Status 35
Table 57: HCC Panel - Product Description 35
Table 58: ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 36
Table 59: HepatoDetect Diagnostic Kit - Product Status 36
Table 60: HepatoDetect Diagnostic Kit - Product Description 36
Table 61: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 37
Table 62: Diagnostic Assay - HCC - Product Status 37
Table 63: Diagnostic Assay - HCC - Product Description 37
Table 64: IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 38
Table 65: Diagnostic Test - Hepatocellular Carcinoma - Product Status 38
Table 66: Diagnostic Test - Hepatocellular Carcinoma - Product Description 38
Table 67: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
Table 68: VeraMarker LCS (Liver Cancer Screening) Test - Product Status 39
Table 69: VeraMarker LCS (Liver Cancer Screening) Test - Product Description 39
Table 70: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Status 40
Table 71: VeraMarker Liver Cancer Screening Test - Hepatitis - Product Description 40
Table 72: NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 73: In Vitro Diagnostic Assay - HCC Gene Signature - Product Status 41
Table 74: In Vitro Diagnostic Assay - HCC Gene Signature - Product Description 41
Table 75: National Cancer Institute US Pipeline Products & Ongoing Clinical Trials Overview 42
Table 76: HCC Gene Signature Diagnostic Test - Product Status 42
Table 77: HCC Gene Signature Diagnostic Test - Product Description 42
Table 78: HCC Gene Signature Prognostic Test - Product Status 43
Table 79: HCC Gene Signature Prognostic Test - Product Description 43
Table 80: Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 44
Table 81: EarlyCDT - Liver Cancer - Product Status 44
Table 82: EarlyCDT - Liver Cancer - Product Description 44
Table 83: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45
Table 84: Diagnostic Assay - Liver Cancer - Product Status 45
Table 85: Diagnostic Assay - Liver Cancer - Product Description 45
Table 86: PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 46
Table 87: HCCpleX - Product Status 46
Table 88: HCCpleX - Product Description 46
Table 89: ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 90: Screening Test - Liver Cancer - Product Status 47
Table 91: Screening Test - Liver Cancer - Product Description 47
Table 92: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 48
Table 93: Biomarker Diagnostic Test - Liver Cancer - Product Status 48
Table 94: Biomarker Diagnostic Test - Liver Cancer - Product Description 48
Table 95: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 49
Table 96: Biomarker Assay - Liver Cancer - Product Status 49
Table 97: Biomarker Assay - Liver Cancer - Product Description 49
Table 98: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
Table 99: Cobas 8000 Analyzer Series With e 801 Module - PIVKA Assay - Product Status 50
Table 100: Cobas 8000 Analyzer Series With e 801 Module - PIVKA Assay - Product Description 50
Table 101: Glypican-3 MAb Companion Diagnostic Test - Product Status 51
Table 102: Glypican-3 MAb Companion Diagnostic Test - Product Description 51
Table 103: University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 52
Table 104: Biomarker Test - HCC - Product Status 52
Table 105: Biomarker Test - HCC - Product Description 52
Table 106: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 53
Table 107: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Status 53
Table 108: BLU-554 Companion Diagnostic Assay - Hepatocellular Carcinoma - Product Description 53
Table 109: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 54
Table 110: Diagnostic Assay - Liver Cancer - Product Status 54
Table 111: Diagnostic Assay - Liver Cancer - Product Description 54
Table 112: XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 55
Table 113: compleXima HCC Biochip - Liver Cancer - Product Status 55
Table 114: compleXima HCC Biochip - Liver Cancer - Product Description 55
Table 115: DCP-IgM Kit - Liver Cancer - Product Status 56
Table 116: DCP-IgM Kit - Liver Cancer - Product Description 56
Table 117: GPC3-IgM Kit - Liver Cancer - Product Status 56
Table 118: GPC3-IgM Kit - Liver Cancer - Product Description 57
Table 119: Osteopontin-IgM Kit - Liver Cancer - Product Status 57
Table 120: Osteopontin-IgM Kit - Liver Cancer - Product Description 57
Table 121: Survivin-IgM Kit - Liver Cancer - Product Status 58
Table 122: Survivin-IgM Kit - Liver Cancer - Product Description 58
Table 123: VEGF-IgM Kit - Liver Cancer - Product Status 58
Table 124: VEGF-IgM Kit - Liver Cancer - Product Description 59
Table 125: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
Table 126: Theranostic - Liver Cancer Metastasis - Product Status 60
Table 127: Theranostic - Liver Cancer Metastasis - Product Description 60
Table 128: Glossary 135

1.2 List of Figures
Figure 1: Liver Cancer Diagnostic Tests - Pipeline Products by Stage of Development 9
Figure 2: Liver Cancer Diagnostic Tests - Pipeline Products by Territory 10
Figure 3: Liver Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 11
Figure 4: Liver Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 12
Filed in: Medical Device
Publisher : GlobalData